Esperion Therapeutics Inc

Financials

Cash from operating activities 85.18 M263.81 M174.83 M135.49 M23.65 M 70.69 M Cash from investing activities 21.36 M50.48 M8.1 M42.5 M317 K 0 Cash from financing activities 201.72 M268.22 M32.61 M50.46 M86.48 M 41.02 M Free cash flow 84.31 M263.81 M174.83 M135.49 M23.34 M 70.69 M

Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.

ESPR

Financials

Esperion Therapeutics Inc

Haberler

Esperion Therapeutics (ESPR) Earnings Expected to Grow: Should You Buy?

Esperion hisseleri, InvestingPro’nun Nisan 2024 Gerçek Değer tahmini sonrası %77 kazanç sağladı

Esperion stock delivers 77% gain since InvestingPro’s April 2024 Fair Value call

Esperion, Alkem ile kolesterol ilaçları konusundaki patent anlaşmazlığını çözüme kavuşturdu

Esperion settles patent dispute with Alkem over cholesterol drugs

Esperion Therapeutics genel danışmanı 4,9 bin dolarlık hisse satışı gerçekleştirdi

Esperion Therapeutics general counsel sells $4.9k in stock

H.B. Fuller, Caledonia Mining And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Absci (NASDAQ:ABSI), Buckle (NYSE:BKE)

Esperion Therapeutics, Inc. (ESPR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Intel and Visa among market cap stock movers on Tuesday

Esperion hisseleri, InvestingPro’nun Nisan 2024 Gerçek Değer tahmini sonrası %77 kazanç sağladı

Esperion stock delivers 77% gain since InvestingPro’s April 2024 Fair Value call